AU2004271706B2 - Factor IXa specific antibodies displaying factor VIIIa like activity - Google Patents

Factor IXa specific antibodies displaying factor VIIIa like activity Download PDF

Info

Publication number
AU2004271706B2
AU2004271706B2 AU2004271706A AU2004271706A AU2004271706B2 AU 2004271706 B2 AU2004271706 B2 AU 2004271706B2 AU 2004271706 A AU2004271706 A AU 2004271706A AU 2004271706 A AU2004271706 A AU 2004271706A AU 2004271706 B2 AU2004271706 B2 AU 2004271706B2
Authority
AU
Australia
Prior art keywords
antibody
factor
antibodies
fixa
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004271706A
Other languages
English (en)
Other versions
AU2004271706A1 (en
Inventor
Randolf Kerschbaumer
Friedrich Scheiflinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34273861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004271706(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2004271706A1 publication Critical patent/AU2004271706A1/en
Application granted granted Critical
Publication of AU2004271706B2 publication Critical patent/AU2004271706B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2004271706A 2003-09-12 2004-09-07 Factor IXa specific antibodies displaying factor VIIIa like activity Expired AU2004271706B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/661,366 2003-09-12
US10/661,366 US7297336B2 (en) 2003-09-12 2003-09-12 Factor IXa specific antibodies displaying factor VIIIa like activity
PCT/EP2004/009975 WO2005025615A2 (en) 2003-09-12 2004-09-07 FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY

Publications (2)

Publication Number Publication Date
AU2004271706A1 AU2004271706A1 (en) 2005-03-24
AU2004271706B2 true AU2004271706B2 (en) 2010-09-02

Family

ID=34273861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004271706A Expired AU2004271706B2 (en) 2003-09-12 2004-09-07 Factor IXa specific antibodies displaying factor VIIIa like activity

Country Status (9)

Country Link
US (1) US7297336B2 (enExample)
EP (1) EP1660536B1 (enExample)
JP (1) JP4887148B2 (enExample)
AT (1) ATE419277T1 (enExample)
AU (1) AU2004271706B2 (enExample)
CA (1) CA2538895A1 (enExample)
DE (1) DE602004018788D1 (enExample)
ES (1) ES2320665T3 (enExample)
WO (1) WO2005025615A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP2824183B1 (en) * 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing bispecific antibodies
EP1760092A1 (en) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
BR112015006634B1 (pt) * 2012-09-28 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Método e kit para avaliação de reação de coagulação sanguínea
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
SG11201809642TA (en) * 2016-05-16 2018-11-29 Baxalta Inc Anti-factor ix padua antibodies
CA3027018A1 (en) 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
CA3034105A1 (en) * 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
AU2017363309A1 (en) * 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
AU2018216008A1 (en) 2017-02-01 2019-08-01 Novo Nordisk A/S Procoagulant antibodies
JP7209298B2 (ja) 2017-03-31 2023-01-20 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient
KR20260090008A (ko) 2017-11-01 2026-06-16 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트 및 아이소폼
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
PE20211399A1 (es) 2018-08-01 2021-07-27 Novo Nordisk As Anticuerpos procoagulantes mejorados
TWI772724B (zh) 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體
WO2021152066A1 (en) 2020-01-30 2021-08-05 Novo Nordisk A/S Bispecific factor viii mimetic antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019992A2 (en) * 1999-09-14 2001-03-22 Baxter Aktiengesellschaft FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0658168T3 (da) 1992-08-27 2001-01-22 Sanquin Bloedvoorziening Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
EP1001991A4 (en) 1997-07-03 2005-01-26 Smithkline Beecham Corp CRYSTALLINE STRUCTURES OF FAB ANTI-FACTOR IX FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019992A2 (en) * 1999-09-14 2001-03-22 Baxter Aktiengesellschaft FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES

Also Published As

Publication number Publication date
US20050058640A1 (en) 2005-03-17
JP2007504812A (ja) 2007-03-08
ES2320665T3 (es) 2009-05-27
WO2005025615A3 (en) 2005-06-02
US7297336B2 (en) 2007-11-20
EP1660536B1 (en) 2008-12-31
DE602004018788D1 (de) 2009-02-12
ATE419277T1 (de) 2009-01-15
JP4887148B2 (ja) 2012-02-29
WO2005025615A2 (en) 2005-03-24
CA2538895A1 (en) 2005-03-24
AU2004271706A1 (en) 2005-03-24
EP1660536A2 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
US7297336B2 (en) Factor IXa specific antibodies displaying factor VIIIa like activity
JP6944509B2 (ja) Ｉｌ−１８結合分子
JP4313531B2 (ja) 第ＩＸ因子／第ＩＸａ因子の抗体および抗体誘導体
EP2542257B1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2011001351A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular.
TW201536810A (zh) 結合尿激酶纖維蛋白溶酶原活化物之抗體
US10144784B2 (en) Monoclonal antibodies against antithrombin beta
CN114773473A (zh) 抗cd39抗体及其制备方法和用途
US7858089B2 (en) Antibodies binding to the A2 domain of FVIII and inhibiting coagulation activity
US20060177446A1 (en) Polypeptides that bind an anti-tissue factor antibody and uses thereof
Eigenbrot et al. Structural insight into how an anti-idiotypic antibody against D3H44 (anti-tissue factor antibody) restores normal coagulation
AU2022289196A1 (en) Novel antithrombotic antibody
AU2016269554B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
KR20230142724A (ko) 인자 XIa 억제제에 대한 항체 및 항원 결합 펩티드및 그의 용도
WO2015004148A1 (en) Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
HK1156635A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 07 SEP 2014 TO 07 APR 2015 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 07 APR 2015 .

PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): BAXTER HEALTHCARE S.A.; BAXTER INTERNATIONAL INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired